



Serving CROs, R&D and Biopharmaceutical Companies

ONCOtracker provides testing services to support your drug development needs



Since
2015

Recent Program Successes



Discovery and development of a novel serum B-cell biomarker for multiple myeloma with applications being developed in other cancers and diseases



Pharmacologic method to potentiate the efficacy of BiTE and ADC therapies targeting BCMA



Combination of available drugs that produce high response rates in heavily treated myeloma patients



WHAT WE DO



**IMMUNOASSAY
TESTING**



**BIOSPECIMENS
PROVISIONS**



**PATIENT-DERIVED
XENOGRRAFT**



**CONSULTATIVE
SERVICES**



sBCMA BIOMARKER ASSAY


ONCOtracker's sBCMA assay is used in pre-clinical and phase 1 to 3 studies investigating response to drug therapies. Nearly 20,000 samples have been tested.

sBCMA utility in key areas of investigation:


- ◆ BCMA-directed drug development
- ◆ Monitoring response to therapy
- ◆ Predicting response to therapy

Advantages of sBCMA

- ◆ Independent of kidney function
- ◆ Useful in non-secretory and oligo secretory MM
- ◆ Short half-life for tighter monitoring of changes
- ◆ Found in MGUS, smoldering myeloma, CLL, and other B-cell malignancies



IMMUNOASSAY



Proprietary sBCMA assay for BCMA-directed drug development, patient monitoring and prediction of response to treatment

Our GLP-laboratory is newly designed and operated to produce high quality test results while maintaining data integrity and regulatory compliance

TEST MENU:

- ◆ **sBCMA:** Solubilized B-Cell Maturation Antigen
- ◆ **BAFF:** B-Cell Activating Factor
- ◆ **APRIL:** A Proliferation Inducing Ligand
- ◆ **Other:** Cytokines and Chemokines

Custom assay development and validation is available upon request



BIOSPECIMENS



Retrospective, longitudinal, frequently collected specimens with comprehensive clinical data

We provide access to a world-class biorepository of clinically characterized specimens from thousands of multiple myeloma patients

SPECIMEN TYPES INCLUDE:

◆ Plasma ◆ Serum ◆ Bone Marrow ◆ PBMCs

We incorporate comprehensive clinical data including demographics, treatment history, clinical response, laboratory results, pathology reports and physician notes to support precision medicine research

Prospective collection capabilities available upon request



PATIENT-DERIVED XENOGRAPHS (PDX)

Production of five (5) PDX animal models uniquely derived from fresh multiple myeloma human tumor samples from patient's with diverse background

PDX MODELS OFFERING:

- ◆ Intramuscular heterotopic multiple myeloma model
- ◆ Complete records on patient's background and treatment history
- ◆ Further molecular and characterization studies on the developed tumors
- ◆ Identification and recording biomarkers predicting treatment response



CONSULTATIVE SERVICES



Experienced team in myeloma research & assay development

Our exceptional team of myeloma drug discovery and development scientists, clinicians and laboratorians can help you address your testing needs

Expertise in:

- ◆ Study design and protocol writing
- ◆ Access to clinical sites for obtaining biospecimens
- ◆ Biorepository with comprehensive, longitudinal clinical data
- ◆ Collaborations with large cancer centers
- ◆ Assay development specific to myeloma and other B-cell malignancies



ONCOtracker GLP-Compliant Laboratory



ONCOtracker's facilities in Los Angeles, CA include a state-of-the-art GLP Laboratory and Biorepository. These are ideally suited to support drug development and clinical studies worldwide with rapid turnaround time of testing results.

■ GLP-compliant Laboratory

- Immunoassay and molecular capabilities
- Secure, card-keyed access
- Experienced laboratorians, scientists and project coordinators

■ Biorepository

- Over 20,000 clinically characterized retrospective specimens
- Comprehensive clinical data on all serially collected samples
- Prospective collection and storage capabilities

ONCOtracker Biorepository



James R. Berenson, M.D.

Founder and Laboratory Director

- Professor of Medicine. Dept. of Medicine / Div. of Hematology-Oncology. UCLA School of Medicine (1982-2000)
- Director of Myeloma Program at Cedars-Sinai Medical Center (2000-2003)
- Founder and President of the Institute for Myeloma and Bone Cancer Research (2003-present)
- Founder and CEO of ONCOtherapeutics (2003-present)
- Published more than 300 peer-reviewed articles in top scientific and clinical
- Published two books on multiple myeloma





Eric Souther

Business Development

9201 Sunset Blvd, Suite 300
West Hollywood, CA 90069



424.204.0726



info@oncotracker.com



www.oncotracker.com

